HomeCompareLYT vs ABBV

LYT vs ABBV: Dividend Comparison 2026

LYT yields 2036.66% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LYT wins by $11772545477.08M in total portfolio value
10 years
LYT
LYT
● Live price
2036.66%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11772545477.19M
Annual income
$10,735,622,494,080,630.00
Full LYT calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LYT vs ABBV

📍 LYT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLYTABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LYT + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LYT pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LYT
Annual income on $10K today (after 15% tax)
$173,116.09/yr
After 10yr DRIP, annual income (after tax)
$9,125,279,119,968,536.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, LYT beats the other by $9,125,279,119,947,480.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LYT + ABBV for your $10,000?

LYT: 50%ABBV: 50%
100% ABBV50/50100% LYT
Portfolio after 10yr
$5886272738.64M
Annual income
$5,367,811,247,052,701.00/yr
Blended yield
91.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LYT
No analyst data
Altman Z
1.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LYT buys
0
ABBV buys
0
No recent congressional trades found for LYT or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLYTABBV
Forward yield2036.66%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$11772545477.19M$102.3K
Annual income after 10y$10,735,622,494,080,630.00$24,771.77
Total dividends collected$11699050861.70M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LYT vs ABBV ($10,000, DRIP)

YearLYT PortfolioLYT Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$214,366$203,665.99$11,550$430.00+$202.8KLYT
2$4,309,658$4,080,286.04$13,472$627.96+$4.30MLYT
3$81,275,731$76,664,397.07$15,906$926.08+$81.26MLYT
4$1,438,191,233$1,351,226,200.72$19,071$1,382.55+$1438.17MLYT
5$23,884,876,948$22,346,012,329.56$23,302$2,095.81+$23884.85MLYT
6$372,391,587,437$346,834,769,102.47$29,150$3,237.93+$372391.56MLYT
7$5,452,231,676,838$5,053,772,678,280.18$37,536$5,121.41+$5452231.64MLYT
8$74,986,145,927,739$69,152,258,033,522.16$50,079$8,338.38+$74986145.88MLYT
9$969,086,900,097,602$888,851,723,954,921.50$69,753$14,065.80+$969086900.03MLYT
10$11,772,545,477,185,064$10,735,622,494,080,630.00$102,337$24,771.77+$11772545477.08MLYT

LYT vs ABBV: Complete Analysis 2026

LYTStock

Lytus Technologies Holdings Private Limited, a platform services company, provides content streaming/telecasting services to users in India. Its Lytus platform provides a range of streaming services and telemedicine services with local assistance through health centers. The company through its platform enable its customers to connect via CPE devices/STBs and have access to multi-dimensional services, including telemedicine service. The company was incorporated in 2020 and is headquartered in Mumbai, India.

Full LYT Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LYT vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LYT vs SCHDLYT vs JEPILYT vs OLYT vs KOLYT vs MAINLYT vs JNJLYT vs MRKLYT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.